{
    "clinical_study": {
        "@rank": "31649", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This multicenter, prospective, observational study will evaluate the efficacy and safety of\n      Pegasys (peginterferon alfa-2a) in routine clinical practice in patients with HBeAg-positive\n      or HBeAg-negative chronic hepatitis B. Eligible patients receiving treatment with Pegasys\n      according to standard of care and the summary od product characteristics/local labelling\n      will be followed for the duration of treatment and up to 2 years of follow-up."
        }, 
        "brief_title": "An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B", 
        "completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "condition": "Hepatitis B, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  HBeAg-positive or HBeAg-negative serologically proven chronic hepatitis B with or\n             without cirrhosis\n\n          -  Elevated serum ALT > ULN (upper limit of normal) but </=10 x ULN according to local\n             label\n\n        Exclusion Criteria:\n\n          -  Contra-indications to Pegasys as detailed in the label\n\n          -  Co-infection with hepatitis A, hepatitis B or HIV\n\n          -  Concomitant therapy with telbivudine (concomitant peginterferon alfa-2a therapy is\n             contra-indicated according to telbivudine label)\n\n          -  Pregnant or breastfeeding women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with chronic hepatitis B receiving treatment with Pegasys"
            }
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01734018", 
            "org_study_id": "ML25614"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Peginterferon alfa-2a", 
                "Interferon-alpha"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "13353"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "zip": "04103"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Multicenter, Prospective, Non-Interventional Study Evaluating Response Parameters During and After Therapy With PEGASYS (Peginterferon Alfa-2a 40KD) in Subjects With HBeAg Positive or HBeAg Negative Chronic Hepatitis B", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Change in HBsAg (IU/ml) levels during therapy (up to 48 weeks) and follow-up", 
                "safety_issue": "No", 
                "time_frame": "from baseline to up to approximately 3 years"
            }, 
            {
                "measure": "Change in HBV DNA (IU/ml) during therapy (up to 48 weeks) and follow-up", 
                "safety_issue": "No", 
                "time_frame": "from baseline to up to approximately 3 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01734018"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of patients with sustained immune control (sustained HBV DNA <2000 IU/ml in HBeAg-negative and HBeAg-positive patients or HBeAg seroconversion in HBeAg-positive patients)", 
                "safety_issue": "No", 
                "time_frame": "approximately 4 years"
            }, 
            {
                "measure": "Percentage of patients with normalisation of serum alanine transaminase (ALT) levels", 
                "safety_issue": "No", 
                "time_frame": "approximately 4 years"
            }, 
            {
                "measure": "Percentage of patients with HBsAg clearance/seroconversion", 
                "safety_issue": "No", 
                "time_frame": "approximately 4 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 4 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}